Carbogen Amcis Receives Clean Slate from FDA

Swiss pharmaceutical powerhouse, Carbogen Amcis, has emerged triumphant from the rigorous inspection process conducted by the U.S. Food and Drug Administration (FDA). Both its Neuland and Aarau manufacturing facilities have earned spotless reports, a testament to the company's unwavering dedication to pharmaceutical excellence.

The FDA's meticulous five-day examination of Neuland and three-day evaluation of Aarau concluded without any critical findings or recommendations for improvement. This exceptional outcome is a direct result of Carbogen Amcis' robust quality management systems, state-of-the-art facilities, and highly skilled workforce.

Pascal Villemagne, CEO of Carbogen Amcis, expressed immense pride in the company's achievement. He emphasized that this FDA success reinforces Carbogen Amcis' position as a leading provider of high-quality pharmaceutical products and services. Arpit Vyas, Global Managing Director of the Dishman Group, echoed these sentiments, attributing the accomplishment to the tireless efforts of the entire team.

This FDA approval is a significant milestone for Carbogen Amcis, solidifying its reputation as a trusted partner to pharmaceutical companies worldwide. It demonstrates the company's ability to consistently meet and exceed the most stringent regulatory standards, ensuring the safety and efficacy of its products.